189 related articles for article (PubMed ID: 37871911)
21. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
22. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Old JB; Kratzat S; Hoellein A; Graf S; Nilsson JA; Nilsson L; Nakayama KI; Peschel C; Cleveland JL; Keller UB
Mol Cancer Res; 2010 Mar; 8(3):353-62. PubMed ID: 20197382
[TBL] [Abstract][Full Text] [Related]
23. SKP2 Activation by Thyroid Hormone Receptor β2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells.
Xu XL; Li Z; Liu A; Fan X; Hu DN; Qi DL; Chitty DW; Jia R; Qui J; Wang JQ; Sharaf J; Zou J; Weiss R; Huang H; Joseph WJ; Ng L; Rosen R; Shen B; Reid MW; Forrest D; Abramson DH; Singer S; Cobrinik D; Jhanwar SC
Cancer Res; 2017 Dec; 77(24):6838-6850. PubMed ID: 28972075
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenomics and chemical library screens reveal a novel SCF
Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and immunological significance of an M1 macrophage-related gene signature in osteosarcoma.
Mao X; Song F; Jin J; Zou B; Dai P; Sun M; Xu W; Wang L; Kang Y
Front Immunol; 2023; 14():1202725. PubMed ID: 37465666
[TBL] [Abstract][Full Text] [Related]
28. Saurolactam Inhibits Proliferation, Migration, and Invasion of Human Osteosarcoma Cells.
Li Z; Liu H; Li B; Zhang Y; Piao C
Cell Biochem Biophys; 2015 Jul; 72(3):719-26. PubMed ID: 25627547
[TBL] [Abstract][Full Text] [Related]
29. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
30. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas.
Huang HY; Kang HY; Li CF; Eng HL; Chou SC; Lin CN; Hsiung CY
Clin Cancer Res; 2006 Jan; 12(2):487-98. PubMed ID: 16428491
[TBL] [Abstract][Full Text] [Related]
31. Skp2 suppresses p53-dependent apoptosis by inhibiting p300.
Kitagawa M; Lee SH; McCormick F
Mol Cell; 2008 Feb; 29(2):217-31. PubMed ID: 18243116
[TBL] [Abstract][Full Text] [Related]
32. MYC regulates CSF1 expression via microRNA 17/20a to modulate tumor-associated macrophages in osteosarcoma.
Nirala BK; Patel TD; Kurenbekova L; Shuck R; Dasgupta A; Rainusso N; Coarfa C; Yustein JT
JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37279073
[TBL] [Abstract][Full Text] [Related]
33. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
34. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Agarwal A; Bumm TG; Corbin AS; O'Hare T; Loriaux M; VanDyke J; Willis SG; Deininger J; Nakayama KI; Druker BJ; Deininger MW
Blood; 2008 Sep; 112(5):1960-70. PubMed ID: 18559973
[TBL] [Abstract][Full Text] [Related]
35. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.
Zuo T; Liu R; Zhang H; Chang X; Liu Y; Wang L; Zheng P; Liu Y
J Clin Invest; 2007 Dec; 117(12):3765-73. PubMed ID: 18008005
[TBL] [Abstract][Full Text] [Related]
36. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
Jamal A; Swarnalatha M; Sultana S; Joshi P; Panda SK; Kumar V
Cell Cycle; 2015; 14(16):2688-700. PubMed ID: 26038816
[TBL] [Abstract][Full Text] [Related]
37. Skp2 regulates G2/M progression in a p53-dependent manner.
Hu R; Aplin AE
Mol Biol Cell; 2008 Nov; 19(11):4602-10. PubMed ID: 18716061
[TBL] [Abstract][Full Text] [Related]
38. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
39. NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21/p27 axis.
Shen L; Qu X; Li H; Xu C; Wei M; Wang Q; Ru Y; Liu B; Xu Y; Li K; Hu J; Wang L; Ma Y; Li M; Lai X; Gao L; Wu K; Yao L; Zheng J; Zhang J
Oncogene; 2018 Mar; 37(13):1759-1774. PubMed ID: 29343851
[TBL] [Abstract][Full Text] [Related]
40. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
He L; Yang H; Huang J
BMC Cancer; 2021 May; 21(1):581. PubMed ID: 34016089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
